The interaction of diltiazem with lovastatin and pravastatin (Q77495508)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797793%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

title

The interaction of diltiazem with lovastatin and pravastatin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797793%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

Azie NE

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797793%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Brater DC

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797793%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Becker PA

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797793%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Jones DR

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797793%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Hall SD

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797793%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 October 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797793%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797793%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797793%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797793%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

369-377

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797793%20AND%20SRC:MED&resulttype=core&format=json

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Diltiazem enhances the effects of triazolam by inhibiting its metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Pharmacokinetic Interactions with Calcium Channel Antagonists (Part II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Efficacy and long-term adverse effect pattern of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

High-performance liquid chromatographic assay of diltiazem and six of its metabolites in plasma: application to a pharmacokinetic study in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Effects of simvastatin and pravastatin on 6 beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Biotransformation of lovastatin--III. Effect of cimetidine and famotidine on in vitro metabolism of lovastatin by rat and human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

In vitro forecasting of drugs which may interfere with the biotransformation of midazolam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Pharmacokinetic interaction between cyclosporin and diltiazem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Dose of midazolam should be reduced during diltiazem and verapamil treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Steady-state plasma concentrations of diltiazem and its metabolites in patients and healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990067-4

10.1016/S0009-9236(98)90067-4

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797793%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference